- Home
- ACRV vs IGC Comparison
ACRV vs IGC Comparison
Compare ACRV & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- IGC
- Stock Information
- Founded
- ACRV 2018
- IGC 2005
- Country
- ACRV United States
- IGC United States
- Employees
- ACRV N/A
- IGC N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- ACRV Health Care
- IGC Health Care
- Exchange
- ACRV Nasdaq
- IGC Nasdaq
- Market Cap
- ACRV 47.8M
- IGC 39.8M
- IPO Year
- ACRV 2022
- IGC N/A
- Fundamental
- Price
- ACRV $1.89
- IGC $0.37
- Analyst Decision
- ACRV Buy
- IGC Strong Buy
- Analyst Count
- ACRV 6
- IGC 2
- Target Price
- ACRV $17.75
- IGC $4.00
- AVG Volume (30 Days)
- ACRV 1.1M
- IGC 974.7K
- Earning Date
- ACRV 11-07-2025
- IGC 11-14-2025
- Dividend Yield
- ACRV N/A
- IGC N/A
- EPS Growth
- ACRV N/A
- IGC N/A
- EPS
- ACRV N/A
- IGC N/A
- Revenue
- ACRV N/A
- IGC $1,327,000.00
- Revenue This Year
- ACRV N/A
- IGC $3.54
- Revenue Next Year
- ACRV $805.34
- IGC $15.12
- P/E Ratio
- ACRV N/A
- IGC N/A
- Revenue Growth
- ACRV N/A
- IGC 24.95
- 52 Week Low
- ACRV $1.05
- IGC $0.25
- 52 Week High
- ACRV $8.74
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- ACRV 48.13
- IGC 37.66
- Support Level
- ACRV $1.91
- IGC $0.38
- Resistance Level
- ACRV $2.46
- IGC $0.45
- Average True Range (ATR)
- ACRV 0.17
- IGC 0.03
- MACD
- ACRV -0.02
- IGC -0.00
- Stochastic Oscillator
- ACRV 15.69
- IGC 33.25
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.